Oncology clinical trials in the time of COVID-19: how a pandemic can revolutionize patients’ care

di Massari, Francesco, Mollica, Veronica, Salvagni, Stefania, Tognetto, Michele, Ardizzoni, Andrea
Pubblicato in Future Oncol (2020)

A 5-year retrospective longitudinal study on the incidence and the risk factors of osteonecrosis of the jaws in patients treated with zoledronic acid for bone metastases from solid...

di Manfredi, Maddalena, Mergoni, Giovanni, Goldoni, Matteo, Salvagni, Stefania, Merigo, Elisabetta, Meleti, Marco, Vescovi, Paolo
Pubblicato in Med Oral Patol Oral Cir Bucal (2017)

Evolution of cystic airspaces lung lesions on immune checkpoint inhibition in non-small cell lung cancer

di Parisi, Claudia, Lamberti, Giuseppe, Zompatori, Maurizio, Gelsomino, Francesco, Salvagni, Stefania, Sperandi, Francesca, Ardizzoni, Andrea
Pubblicato in J Immunother Cancer (2020)

The Complex Management of Atrial Fibrillation and Cancer in the COVID-19 Era: Drug Interactions, Thromboembolic Risk, and Proarrhythmia

di Gatti, Milo, Raschi, Emanuel, Poluzzi, Elisabetta, Martignani, Cristian, Salvagni, Stefania, Ardizzoni, Andrea, Diemberger, Igor
Pubblicato in Curr Heart Fail Rep (2020)

Open-Label, Phase II, Multicenter, Randomized Study of the Efficacy and Safety of Two Dose Levels of Pertuzumab, a Human Epidermal Growth Factor Receptor 2 Dimerization Inhibitor,...

di Gianni, Luca, Lladó, Anna, Bianchi, Giulia, Cortes, Javier, Kellokumpu-Lehtinen, Pirkko-Liisa, Cameron, David A., Miles, David, Salvagni, Stefania, Wardley, Andrew, Goeminne, Jean-Charles, Hersberger, Veronica, Baselga, José
Pubblicato in J Clin Oncol (2010)

A Phase II Randomized Dose Escalation Trial of Sorafenib in Patients With Advanced Hepatocellular Carcinoma

di Rimassa, Lorenza, Pressiani, Tiziana, Boni, Corrado, Carnaghi, Carlo, Rota Caremoli, Elena, Fagiuoli, Stefano, Foa, Paolo, Salvagni, Stefania, Cortesi, Enrico, Chiara Tronconi, Maria, Personeni, Nicola, Bozzarelli, Silvia, Chiara Banzi, Maria, Fanello, Silvia, Romano Lutman, Fabio, Giordano, Laura, Santoro, Armando
Pubblicazione 2013

A Phase 1 Study of mTORC1/2 Inhibitor BI 860585 as a Single Agent or with Exemestane or Paclitaxel in Patients with Advanced Solid Tumors

di de Braud, Filippo, Machiels, Jean-Pascal H., Boggiani, Daniela, Rottey, Sylvie W.H., Duca, Matteo, Laruelle, Marie, Salvagni, Stefania, Damian, Silvia, Lapeire, Lore D.F., Tiseo, Marcello, Dermine, Alexandre, Ould-Kaci, Mahmoud, Braunger, Juergen, Rascher, Juliane, Fischer, Daniela, Hoefler, Josef, Mariani, Gabriella L., Cresta, Sara
Pubblicato in Cancers (Basel) (2020)

Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib

di Rimassa, Lorenza, Abbadessa, Giovanni, Personeni, Nicola, Porta, Camillo, Borbath, Ivan, Daniele, Bruno, Salvagni, Stefania, Van Laethem, Jean-Luc, Van Vlierberghe, Hans, Trojan, Jörg, De Toni, Enrico N., Weiss, Alan, Miles, Steven, Gasbarrini, Antonio, Lencioni, Monica, Lamar, Maria E., Wang, Yunxia, Shuster, Dale, Schwartz, Brian E., Santoro, Armando
Pubblicato in Oncotarget (2016)